Overview

A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate rising dose levels of VS-5584 administered in combination with a fixed dose of VS-6063 in subjects with relapsed malignant mesothelioma to determine a recommended Phase 2 dose (RP2D) for further development of this combination in this indication.
Phase:
Phase 1
Details
Lead Sponsor:
Verastem, Inc.